Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

HALO

Halozyme Thrp

NASDAQ

39.69

+1.08

+2.80%

After Hours: 39.69 0 0.00% 16:20 12/01 EST

OPEN

38.81

PREV CLOSE

38.61

HIGH

39.75

LOW

38.49

VOLUME

1.02M

TURNOVER

52 WEEK HIGH

59.46

52 WEEK LOW

29.85

MARKET CAP

5.24B

P/E (TTM)

21.21

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)

TipRanks · 4d ago

argenx slips as autoimmune disorder therapy fails in pivotal trial

Argenx se's autoimmune disorder therapy vyvgart hytrulo fails in pivotal trial for adults with primary immune thrombocytopenia. The company says the drug failed to reach primary and secondary endpoints. Argenx has a partnership with chinese biotech zai lab to commercialize the drug in china.

Seeking Alpha · 5d ago

Weekly Report: what happened at HALO last week (1120-1124)?

Weekly Report · 6d ago

Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now

NASDAQ · 11/20 17:45

Weekly Report: what happened at HALO last week (1113-1117)?

Weekly Report · 11/20 09:12

Possible Bearish Signals With Halozyme Therapeutics Insiders Disposing Stock

Halozyme therapeutics, inc. Insiders have sold a lot of shares in the last year. The biggest insider sale was for us$1.7m worth of shares at a price of us$58.80 each. Independent director matthew posard made the biggest sale in the past year. But the company's insider selling of shares may not be a cause for concern.

Simply Wall St · 11/19 12:57

Teva gains U.S. approval for generic version of osteoporosis injection

Healthcare teva gains u.s. Approval for generic version of osteoporosis injection. Teva's generic equivalent of forteo uses multi-dose pen device from halozyme therapeutics. The product is expected to be available in the market over the coming weeks.

Seeking Alpha · 11/17 14:26

Analysts Offer Insights on Healthcare Companies: Cybin (CYBN), ADMA Biologics (ADMA) and Halozyme (HALO)

TipRanks · 11/17 11:20

About HALO

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company’s proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. The Company’s commercially approved product, Hylenex recombinant (Hylenex), and its ENHANZE partners approved products and product candidates are based on rHuPH20. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that is designed to provide commercial or functional advantages. It has a commercial portfolio of proprietary products, including XYOSTED, TLANDO and NOCDURNA and partnered commercial products and ongoing product development programs with several pharmaceutical companies.

Webull offers Halozyme Therapeutics, Inc. stock information, including NASDAQ: HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.